Moderna Inc. applied for U.S. emergency authorization for the company’s Covid-19 vaccine after full results from a late-stage study showed mRNA-1273 was 94.1% effective with no serious safety concerns.
Amgen, UCB and Takeda launched a global trial to identify whether any of three different drugs can reduce the severity of Covid-19 in hospitalized patients by moderating the immune system’s response to the disease.
The United States recorded 10,000 coronavirus deaths and more than 1.1 million new cases for the week ended Nov. 29, although state and health officials said the Thanksgiving holiday likely caused numbers to be under-reported.
Moderna announced plans to submit the company’s request to the U.S. Food and Drug Administration for an Emergency Use Authorization (EUA) for the Covid-19 vaccine mRNA-1273 on Nov. 30.
After a Thanksgiving weekend when the number of people traveling through U.S. airports reached the highest total since mid-March, a top government official said some Americans could begin receiving coronavirus vaccinations before Christmas.
With both Pfizer-BioNTech and Moderna’s Covid-19 vaccines at the U.S. Food and Drug Administration awaiting potential Emergency Use Authorization (EUA), airlines are preparing their cargo operations to ship the vaccines.